Sunday, May 15, 2016

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD (full text article from NEJM 2016)

Dear Respiratory Friends great news come from NEJM about dual bronchodilators in COPD!
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA–LAMA regimen in these patients is unclear.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516385#t=article

 

Methods

We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.

Results

 
full text from todays NEJM:

No comments:

Post a Comment